In plain terms

The claim being assessed: Mislocalization and aggregation of TDP-43 and FUS is the principal causal driver of neurodegeneration across ALS-FTD through nuclear loss of function and cytoplasmic toxic gain of function.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The preregistered scope-matched gate SC5 is Γ. Nuclear splicing failure has convergent causal and functional rescue evidence (SC2 Ζ), and physiological mutant-FUS toxicity is context-valid (SC3 Ε). Neither establishes selective macroscopic-aggregate toxicity or principal dual-arm causation across sporadic ALS–FTD. No narrow success silently replaces that broad gate.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

TDP-43 and FUS help regulate RNA. This review separates the effects of losing their normal nuclear functions, moving them into the cytoplasm and forming visible aggregates in ALS and frontotemporal degeneration.

Implications for health and treatment: The preregistered scope-matched gate SC5 is Γ. Nuclear splicing failure has convergent causal and functional rescue evidence (SC2 Ζ), and physiological mutant-FUS toxicity is context-valid (SC3 Ε). Neither establishes selective macroscopic-aggregate toxicity or principal dual-arm causation across sporadic ALS–FTD. No narrow success silently replaces that broad gate.

Limits for individual care: 63 primary reports with 9 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used complete abstracts/status records and selected original partial-body passages. No complete-paper audit or independent scientific peer review is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 63 primary reports; claims: 69; verified: 69; unverified: 0. Verification is bounded attribution. Access: 9 partial-body and 54 complete abstract/status examinations. Literature cutoff: 2026-10-08; source examination UTC date: 2026-10-09. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 5 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

RNA dysfunction and mutant-FUS toxicity are causal in defined systems; aggregate-driven primacy across ALS–FTD remains unproved.

Deciding experiment: In prospectively genotyped sporadic ALS/FTD humanized models, factorially restore nuclear splicing, prevent only large cytoplasmic assembly and alter soluble cytoplasmic abundance while holding total endogenous protein constant. Start after pathology onset and reverse each rescue to test mediation.

Belief versus evidence: The preregistered scope-matched gate SC5 is Γ. Nuclear splicing failure has convergent causal and functional rescue evidence (SC2 Ζ), and physiological mutant-FUS toxicity is context-valid (SC3 Ε). Neither establishes selective macroscopic-aggregate toxicity or principal dual-arm causation across sporadic ALS–FTD. No narrow success silently replaces that broad gate.

Best-supported rival: Nuclear RNA dysfunction as a causal contributor. Donde selective splicing-repressor rescue contrasts with Devoy physiological aggregate-free FUS degeneration: these support different causal routes, so the winner is the scoped RNA-function contributor rather than a single ALS–FTD origin (PMID31332509,29053787).

COMPETING MECHANISTIC MODELS

Rank 1: Nuclear RNA dysfunction as a causal contributor (Ζ). Loss of specific RNA-processing functions damages neuronal maintenance. UG and splice-site edits, human functional correction and fly/mouse splicing-repressor trajectory rescue (PMID26250685,36927019,31332509). The rank and Ζ apply to contribution in tested contexts, not principal initiation across all sporadic disease.

Rank 2: Mislocalized soluble mutant-RBP toxicity (Ε). Physiological mutant FUS can damage neurons before visible aggregates. Endogenous dosage and null/allele-reversal contrasts (PMID29053787,26951610,35075293). Small assemblies are not excluded and restoring WT simultaneously repairs nuclear function.

Rank 3: RNA/chaperone homeostatic failure (Γ). RNA concentration and import/chaperone systems govern material state and localization. RNA buffering, HSP70/HSPB1 and import-receptor interventions (PMID29650702,33335017,36075972,29677512). Disease-initiation necessity is not selectively isolated; broad chaperone/import effects and forced stress remain.

Rank 4: Principal dual-arm aggregate mechanism (Γ). Nuclear loss and cytoplasmic aggregation can reinforce each other. Genetics, pathology and coupled transgene suppression support serious plausibility (PMID17023659,26197969). Physiological aggregate-free disease and incomplete organismal rescue prevent a universal principal aggregate conclusion.

Rank 5: Aggregates as sequestration or quality control (Γ). Large assemblies can sequester more toxic soluble or liquid species. Yeast scanning and fly-eye sequestration discriminate material states (PMID31519910,25088712). Restricted artificial models do not prove protection of native human disease inclusions.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Mislocalization and aggregation of TDP-43 and FUS is the principal causal driver of neurodegeneration across ALS-FTD through nuclear loss of function and cytoplasmic toxic gain of function.

Use the index dual-arm claim, preserving aggregate-specific toxicity as distinct from mislocalization and RNA dysfunction. Broad ALS-FTD generalization gates the nominal score; Alzheimer comorbidity is a separate comparator, not an added universal claim.

Selection: public-interest rank 38 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

Evidence and causal interpretation

The registered review separates native RNA function, mislocalized-protein toxicity and material-state causality. Sixty-three primary reports were examined, including negative models and 2026 functional studies. Tissue prevalence remains descriptive, and no population percentage is inferred from selected case reports.

Neumann and Arai identify TDP pathology (PMID17023659,17084815), while FUS families and FTLD-FUS subtypes define different genetic and tissue scopes (PMID19251627,19251628,21052700). A pathogenic protein-coding allele can establish gene-level etiology without identifying its macroscopic aggregate as the damaging species.

Ling identifies nonconserved cryptic exon repression and rescues TDP-deleted cell survival with an unrelated repressor domain (PMID26250685). Donde extends functional complementation to flies and motor-neuron-null mice (PMID31332509): neonatal AAV9 CTR, compared with GFP or N-terminal TDP controls, improves motor tests and increases median survival by 29 weeks. Two breeder-matched cohorts and blinded assessments support the endpoint; litter-level allocation, injection attrition and prophylactic complete-deletion context limit generalization.

STMN2 studies restore axon regeneration in human neurons (PMID30643292,30643298). Baughn uses GU-site replacement, steric MCP rescue and splice-acceptor edits to discriminate processing mechanisms (PMID36927019). In human neurons, ASOs restore regeneration and lysosome trafficking despite persistent TDP depletion. The mouse experiments restore RNA/protein in a humanized constitutive splice cassette; they do not test ALS motor survival. The same paper finds no cryptic STMN2 effect in a mutant TDP model retaining nuclear function.

Independent UNC13A studies join human risk variation with cryptic splicing and RNA-binding-dependent rescue (PMID35197626,35197628). Ma reports a subtle difference from Brown in in vitro binding results, attributable in part to full-length versus RRM constructs; this is retained rather than smoothed into perfect agreement. Multitarget ASOs in 2026 restore human-neuron synaptic function (PMID42234776), while KCNQ2 and translated cryptic peptides expand downstream mechanisms (PMID41174170,38277467,41720774). Those endpoints have different burdens from organismal course.

STMN2 conditional loss affects motor-unit maintenance, conduction and denervation (PMID35767949,37996528). It need not cause motor-neuron death to be causally important. Tardbp knockout and acetyl-mimic models independently test RNA function (PMID22718760,37819053), but losing an essential protein or introducing a mimic does not establish the native sporadic initiating event.

FUS gain is supported by endogenous mutant versus null comparisons and selective allele reversal (PMID26951610,28243725). In the neonatal homozygous model, motor-cell bodies recover when mutant alleles become WT, but lethality does not. In an adult single-copy model, cell bodies recover while symptoms are only delayed. These interventions simultaneously remove mutant FUS and restore nuclear function, so compartment-specific causality is not fully separated.

Devoy measures equal total FUS abundance in heterozygous Delta14 mice and progressive motor-neuron loss without visible inclusions or detected insoluble FUS at tested ages (PMID29053787). Arnold similarly finds mutant-TDP disease without large aggregates or nuclear depletion, but uses a near-endogenous-pattern transgene (PMID23382207). These are boundaries on macroscopic necessity, not evidence that every small toxic assembly is absent. Shared Delta14 follow-ups do not become independent model replications.

Korobeynikov uses allele-dose and cell-restricted knock-in contrasts and a P1 20 microgram ION363 injection (PMID35075293). Lowering total FUS prevents motor-neuron loss, denervation and microgliosis while ASO activity persists; waning exposure permits partial pathology return. Initial heterozygotes lack an overt motor phenotype, and aggregate burden, soluble FUS and total dose change together. The original single treated patient cannot determine clinical efficacy.

The 12-person expanded-access jacifusen series shows target engagement and large neurofilament reductions with heterogeneous clinical outcomes (PMID40414239). One participant has sustained functional recovery, while many decline; the earlier single patient is included again. Variable doses, pathogenicity classes, timing and lack of randomized control preclude an efficacy conclusion. Neurofilament lowering is not identical to disease reversal.

Material state has credible contrary evidence. Barmada finds diffuse cytoplasmic TDP associated with death while inclusion presence does not raise measured risk in tagged overexpression neurons (PMID20071528). Bolognesi associates solid distal assemblies with less yeast toxicity despite higher protein abundance (PMID31519910). Fly-eye artificial sequestration offers a restricted protective example (PMID25088712). Neither supports a general assertion that native human inclusions are protective.

RNA buffering and HSP/import systems alter condensation and toxicity (PMID29650702,29677512,33335017,36075972), while spatial human staging and CSF cryptic markers refine timing (PMID38443601,38278991). Forced stress, pore repair and postmortem gradients do not themselves identify sporadic initiation. The tournament favors a scoped nuclear RNA-function contributor, with mutant-FUS gain as a second causal route. The principal aggregate-driven dual mechanism across sporadic ALS–FTD remains Γ.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: scope-matched. The preregistered scope-matched gate SC5 is Γ. Nuclear splicing failure has convergent causal and functional rescue evidence (SC2 Ζ), and physiological mutant-FUS toxicity is context-valid (SC3 Ε). Neither establishes selective macroscopic-aggregate toxicity or principal dual-arm causation across sporadic ALS–FTD. No narrow success silently replaces that broad gate. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] UG-dependent cryptic splicing and chimeric repressor cell-survival rescue. Whole-body disease not tested; human mouse target sequences differ.

[2] UNC13A risk variants potentiate TDP-dependent cryptic splicing and protein loss. Natural risk is conditional; erratum38890465 details unaudited.

[4] Endogenous splice-site edits and ASOs restore STMN2 and human axon regeneration. Mouse target engagement is not disease-course rescue; regenerated injury axons are restricted endpoints.

[7] TDP depletion reduces UNC13A; risk haplotypes amplify cryptic exon use and RNA-binding competent rescue. Human survival association not randomized rescue; binding assay differs from companion Brown paper.

[8] STMN2 loss follows TDP depletion; stabilization restores axonal regeneration. Injury regeneration in culture is not ALS survival.

[9] STMN2 correction restores axon regeneration after nuclear TDP dysfunction. Shared target and culture challenge; disease trajectory untested.

[12] STMN2 is needed for motor-unit maintenance; knockout denervates fast-fatigable NMJs. No motor-neuron or axon degeneration in this model; not full ALS phenocopy.

[13] Blocking mitochondrial TDP import rescues neuronal and behavioral phenotypes. Overexpression and broad mitochondrial intervention do not isolate macroscopic aggregates.

[15] Transgene suppression improves motor course and survival with restoration of nuclear TDP. Both arms and total protein change together; overexpression model.

[16] Ataxin2 deletion or ASO extends survival and lowers pathology. Pleiotropic change does not selectively identify aggregate toxicity.

[17] KCNQ2 cryptic exon produces ER-associated protein and hyperexcitability corrected by ASO. Cell-function rescue not organismal or clinical rescue.

[19] CHMP7 lowering restores pore/Ran/RNA defects and protects against glutamate challenge. Upstream transport perturbation and challenge survival not spontaneous disease course.

[20] Nuclear import receptors counter phase transitions and rescue functional or degenerative outcomes. Import and chaperoning change together across forced models.

[24] Dose and conditional FUS contrasts identify mutant toxicity; P1 ION363 prevents motor-neuron loss and denervation while active. No overt motor phenotype in initial heterozygotes; prophylactic lowering changes soluble and insoluble FUS; one patient cannot establish efficacy.

[30] STMN2 loss alters axon caliber conduction denervation and motor behavior. Not selective rescue of endogenous sporadic TDP disease.

[31] Combined correction of KALRN RAP1GAP SYT7 KCNQ2 nearly restores synaptic function after TDP loss. Multitarget culture rescue not systemic survival; journal report deduplicated from preprint.

[33] Segregating variants support gene-level etiology; engineered developmental toxicity. Gene causality does not prove aggregates or all sporadic mechanism.

[34] FUS mutations segregate in defined ALS families with abnormal localization. Familial etiology is not universal sporadic mechanism.

[35] Multiple familial mutations alter FUS localization. Localization and gene effects remain coupled; no aggregate-selective intervention.

[36] Muscle-intrinsic postsynaptic defects precede motor-neuron loss. Same mutant lineage reused; erratum42463858 details unaudited.

[38] Mutant but not null causes neonatal motor loss; allele reversion rescues cell bodies. Perinatal homozygous model; death not rescued; WT restoration removes mutant and restores nuclear function together.

[39] Mutant gain induces degeneration while postnatal FUS loss alone does not. Transgenic dose and developmental timing constrain generalization.

[42] Motor-neuron WT allele reversion saves cell bodies but only delays symptoms. Residual axonal and neighboring-cell pathology limits whole-course rescue.

[44] Motor-neuron mutant excision prevents cell-body loss but not all axon/glial progression. Cell restriction and incomplete rescue argue against neuron-only single mechanism.

[45] Autoregulation and RNA function are perturbed with cognitive/interneuron phenotypes. KI does not ensure unchanged total dose; erratum29872124 details unaudited.

[53] DBR1-dependent RNA lariats buffer TDP toxicity. Forced expression and RNA pleiotropy; no disease survival.

[56] Conditional loss yields progressive motor-neuron loss and glial activation. Loss of essential protein is not selective cryptic-splicing disruption alone.

[57] A cryptic PKN peptide escaping NMD can impair cognition in an expression model. Ectopic peptide toxicity is not endogenous ALS necessity.

[58] RNA-binding impairment precedes cognitive and pathological progression. Acetyl-mimic mutation is not identical to a natural acetylation state.

[60] Variable TDP loss signatures track nuclear pores; POM121 repair restores RNA function. Cellular repair and donor association not clinical course rescue.

[63] A chimeric splicing repressor rescues motor function and extends mouse median survival by 29 weeks in two cohorts. Neonatal AAV and knockout not sporadic initiation; litter-level randomization and delivery attrition; same Ling programme.

Tally: 31 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Gene-level etiology, RNA restoration, aggregate-state changes and clinical biomarkers are different causal endpoints. Negative aggregate-free/protective contrasts never enter positive-causality tallies.

Cap audit, precedence and Β/Γ/Δ boundary

Convergence licenses Ζ for the precisely tested nuclear RNA-function contribution, including in vivo trajectory rescue; cell-only caps do not erase the assembled case. Those sources cannot upgrade the broader aggregate-specific or sporadic-principal claims. Endogenous mutant FUS supports Ε at its genetic scope; total FUS lowering is not selective aggregate removal.

Gamma hard-rule audit: Overexpression, optogenetics and seeding demonstrate capacity rather than endogenous disease necessity. Physiological abundance is checked empirically; an endogenous knock-in can perturb autoregulation. Transcript or inclusion rescue is separated from motor function, neuron survival and organismal trajectory. Familial FUS or TARDBP etiology does not establish all-sporadic aggregate causation. Macroscopic inclusions, soluble assemblies, liquid condensates and insolubility have distinct measurements.

SC1 cap: “association without temporal or perturbational proof caps at Β.” Original neuropathology establishes distinct pathology classes, but prevalence alone is association and cannot assign causal function. Selected case series do not license population percentages.

SC4 cap: “Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.” Biophysical and forced-assembly toxicity are plausible, but no selective macroscopic-aggregate intervention retaining soluble abundance and nuclear function establishes disease-relevant necessity. Aggregate-free degeneration and restricted protective sequestration are real discriminators.

SC5 cap: “Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.” Postmortem proteinopathy, genotype models and rescues support plausible interacting pathways. No selective model-independent correction establishes this principal aggregate-driven dual mechanism across prespecified sporadic ALS–FTD contexts.

SC1 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Original neuropathology establishes distinct pathology classes, but prevalence alone is association and cannot assign causal function. Selected case series do not license population percentages.

SC2 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. Endogenous TDP depletion, UG/splice-site engineering, RNA-binding competent rescue, human axon/synaptic correction and chimeric-repressor rescue of motor function and survival in flies/mice converge on a functional contribution. Targets are species-specific and knockout rescue does not establish sporadic initiation.

SC3 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. Independent endogenous mutant-FUS lines, null comparisons, cell-restricted allele reversal and FUS lowering identify toxic gain in familial-mutant mouse contexts. Nuclear restoration and mutant removal are coupled; stage and total-dose controls matter.

SC4 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Biophysical and forced-assembly toxicity are plausible, but no selective macroscopic-aggregate intervention retaining soluble abundance and nuclear function establishes disease-relevant necessity. Aggregate-free degeneration and restricted protective sequestration are real discriminators.

SC5 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Postmortem proteinopathy, genotype models and rescues support plausible interacting pathways. No selective model-independent correction establishes this principal aggregate-driven dual mechanism across prespecified sporadic ALS–FTD contexts.

Upward threshold ladder

SC1 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. A prevalence observation remains descriptive; separately trace cell-specific pathology before dysfunction and test its causal correction.

SC2 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes.

SC2 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes.

SC2 Ζ: “Requires: - Multiple independent causal lines in vivo - Replication across at least two relevant systems - Narrowing of major alternative models” Satisfied: yes.

SC2 Η: “Requires: - Strong convergent causal evidence across systems - Intervention-sensitive change in trajectory - No major unresolved contradiction about whether the mechanism is upstream versus downstream” Satisfied: no. Replicate physiological selective splicing-function restoration after onset in independent sporadic contexts with motor/cognitive trajectory endpoints.

SC3 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes.

SC3 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes.

SC3 Ζ: “Requires: - Multiple independent causal lines in vivo - Replication across at least two relevant systems - Narrowing of major alternative models” Satisfied: no. Separate localization from restored nuclear function and total soluble dosage in independent physiological humanized contexts with post-onset rescue.

SC4 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. Block and restore only macroscopic assembly while retaining nuclear RNA processing and soluble protein, then show concordant neuron and disease-course change.

SC5 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. Prospectively stratify sporadic ALS and FTD; selectively correct both arms independently and jointly at endogenous dose, measure temporal mediation and sustained disease-course rescue.

Upper ladder: Endogenous genetics, dose contrasts, cell-restricted allele reversal and therapeutic/prophylactic course endpoints are valid upper-ladder routes. They support narrow RNA/function or mutant-FUS claims without an RCT-only rule. Aggregation-selective restoration and sporadic generalization are still missing.

Independence: Convergence spans sequence-specific causal edits, a genetically linked independent target, in vivo splicing-function complementation and independent axonal-maintenance perturbations. Donde/Ling share a programme; same FUS mouse line and repeated patient cases are explicitly grouped. This is not independent confirmation of the all-sporadic aggregate claim.

Endogenous target-site function [4]: Splice acceptor and steric-binding edits distinguish specific RNA processing from nonspecific whole-protein depletion.

Human genetics and UNC13A functional rescue [7, 2]: Risk haplotype and RNA-binding rescue link an independent human target; some pipelines/cohorts may overlap.

Splicing-repressor trajectory rescue [63]: Unrelated repressor domain rescues fly and mouse motor/lifespan phenotypes rather than merely expression; same Ling programme.

Conditional maintenance loss [12, 30]: Independent STMN2 maintenance perturbations establish axonal/motor functions with endpoints distinct from injury regrowth.

Falsification and pitfalls

Disease occurs without the claimed obligatory feature. Physiological FUSDelta14 motor loss without visible inclusions or detected insoluble FUS (PMID29053787); no inference that all small assemblies are absent. Additional downgrade: False.

Histology reified as toxic species. TDP/FUS pathology presence is graded separately from aggregation-selective causality.

Molecular rescue inflated. Baughn mouse molecular target engagement is not survival rescue; Donde does measure survival.

Near-endogenous equated with endogenous. Arnold transgene and White autoregulatory knock-in have distinct dose limitations.

Shared cases counted as replication. Jacifusen participant 1 and shared FUSDelta14 line are flagged.

Provider citation substitution. Consensus broad Baughn aggregate-free attribution corrected to Arnold/Devoy; journal versions replace preprints.

Adversarial steelman: above, then below

One rung higher Δ: physiological mutant models, genetic etiology and coupled transgene/FUS-lowering rescues suggest genuine disease contribution by RBP dysfunction.

One rung lower Β: proteinopathy is only a postmortem correlate. That ignores the mechanistic and in vivo perturbation/rescue evidence supporting interacting pathways.

Reject Β as the nominal mechanism has functional plausibility beyond correlation; reject Δ for the exact principal aggregate-driven sporadic gate because no matching selective causal perturbation identifies that claim. Keep higher narrow subclaim grades.

Final score, causal direction and M/S/D

The preregistered scope-matched gate SC5 is Γ. Nuclear splicing failure has convergent causal and functional rescue evidence (SC2 Ζ), and physiological mutant-FUS toxicity is context-valid (SC3 Ε). Neither establishes selective macroscopic-aggregate toxicity or principal dual-arm causation across sporadic ALS–FTD. No narrow success silently replaces that broad gate.

For supported RNA/protein dysfunction, pathological feedback can sustain or amplify degeneration downstream of diverse etiologies. Necessity plus sufficiency for all sporadic initiation is absent. Defined familial mutant alleles have etiological force, which does not license the registered broad aggregate-primary role.

Momentum: Mechanistic only. The examined 2025 jacifusen case series and 2026 multitarget cryptic-splicing study are completed reports that test translational and synaptic boundaries, and the jacifusen series records an ongoing efficacy trial; that trial lowers total FUS in familial FUS-ALS and so does not separate material state from nuclear loss of function across sporadic ALS-FTD, which is the registered boundary. No future trial result is presumed, and Momentum modifies neither the level nor the confidence.

Stability: Stable. No named pending result is claimed to move the broad aggregate-primary grade imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

In prospectively genotyped sporadic ALS/FTD humanized models, factorially restore nuclear splicing, prevent only large cytoplasmic assembly and alter soluble cytoplasmic abundance while holding total endogenous protein constant. Start after pathology onset and reverse each rescue to test mediation.

Readout: Single-neuron RNA processing, soluble/insoluble state, axonal and synaptic function, motor/cognitive trajectory and survival. Controls: Abundance-matched WT, aggregate-free mutants, RNA-binding controls, independent cell populations, delivery controls and blinded post-onset phenotyping. Supporting: Both independently specified arms are necessary and joint correction consistently restores disease course across predefined sporadic contexts. Falsifying: Degeneration persists after complete aggregate-only removal with restored splicing, or follows nuclear/soluble dysfunction independently of macroscopic state.

RESEARCH TIMELINE

KNOWLEDGE GAPS

Identify which cytoplasmic species predicts and mediates native neuronal death.

Separate nuclear function from mutant removal during allele reversal.

Test post-onset splicing rescue in physiological sporadic contexts.

Humanize multiple species-specific cryptic targets before systemic inference.

Follow genotype-defined presymptomatic biomarker changes to functional loss.

Resolve cell-body versus axon and glial residual progression.

Replicate protective sequestration in native neuronal disease settings.

Distinguish clinical neurofilament/pathology engagement from efficacy.

Quantify total protein and autoregulation in every knock-in comparison.

Audit linked errata, supplements and inaccessible full bodies before complete-paper publication claims.

METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Provider statements about Methods/Results and any returned passages were compared with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful original-passage comparisons are distinguished from provider summaries and assertions of access. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

REVIEWER NOTES

63 primary reports; nine selected partial-body examinations and 54 complete abstract/status examinations. No complete-paper audit or independent blinded assessment. Five linked errata are flagged with unexamined correction details.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

This is the 2026-10-09 revised edition of a review first issued in hsef_v53_popularity_ranks_36_40_2026-10-08. Findings below mark whether a defect was introduced by that revision or inherited from the original edition.

Scope of checks. All 63 REFERENCES PMIDs verified against PubMed get_article_metadata (63/63 resolve to the stated title, first author, journal and year within the plus-or-minus-1 print/e-pub convention; no retractions or expressions of concern). Thirteen load-bearing claims spot-checked against original abstracts, and the locally held full text of PMID 31332509 was read to check the figure-level survival number that supports the SC2 level. Scoring logic checked: the six universal caps and cap precedence, the pre-registered scope-matched aggregation rule and its reported alternatives, the Beta/Gamma/Delta boundary, the Zeta independence basis, the confidence-band text, the role-of-mechanism derivation, the Momentum artifact requirement and the competing-model tournament fields. Provenance claims in the spliced Consensus block were checked against the 2026-10-06 adversarial summary.

Rejected findings (checked, no change).

1. Reviewer-notes contradiction (the known Oct 9 splice artifact). Checked specifically. This case's REVIEWER NOTES make no claim that Consensus work was absent, and the review carries its own Consensus source log recording signed-in browser use with zero API calls, plus a Consensus reconciliation section. The spliced provenance block is therefore consistent with the preserved notes, and no sentence needed rescoping on that ground. The only false clause in the spliced block was the approval sentence (A1).
2. Scope-matched aggregation (the recurring misread). The declared rule is scope-matched and it is applied correctly as "the highest subclaim whose scope matches the central claim's scope", not as "the highest subclaim". The registered claim is broad - aggregation as the principal driver across ALS-FTD, sporadic included - and SC5 carries that scope at Γ, with SC4 (aggregate material state) also Γ. SC2 Ζ and SC3 Ε are explicitly scope-restricted to endogenous transcript-defined systems and familial-mutant mouse contexts, and the review says in terms that no narrow success silently replaces the broad gate. The reported alternatives are also correct: weakest-link Β is the lowest subclaim (SC1), primary-subclaim Γ. No change.
3. "Best-supported rival" renderer bug. Checked competing_models.models_evaluated: entry 0 is rank 1 with is_nominal: false (Nuclear RNA dysfunction as a causal contributor, Ζ); the nominal is entry 3 at rank 4. The prose names the genuine rank-1 rival. No change.
4. The 29-week survival figure (PMID 31332509). Not in the abstract, which says only "markedly extended their lifespan". The original full text states a "median survival increase of 29 weeks (66%)", with median untreated survival extended from 44 to 73 weeks, and records the blinded rotarod assessment and the two cohorts the review cites. Verified correct.
5. Other load-bearing numbers. PMID 40414239 (12 participants recruited, CSF NfL reduced by up to 82.8% at 6 months, most participants continuing to decline, one with objective functional recovery, one asymptomatic) and PMID 20071528 (inclusion bodies not necessary for toxicity and not affecting risk of cell death; cytoplasmic TDP-43 a strong independent predictor) both match the review's statements, including its refusal to read the case series as an efficacy result.
6. Headline level. Γ was argued up to Δ, on the ground that the FUS allele-reversal and FUS-lowering experiments are endogenous in vivo perturbations with motor-neuron endpoints, and the argument was rejected: those perturbations remove mutant protein and restore nuclear function at the same time, so they do not perturb the registered aggregate-specific arm, and the scope-matched gate is the broad sporadic claim. Β was also rejected because controlled perturbational support is real. Retained.
7. Collective-author and empty-DOI defects. None present.
8. Counts. 63 sources / 69 claims / 69 verified / 0 unverified agree between the banner, scorecard provenance_header and verification_summary. The revision did not alter any count.

Residual limitations. Verification remains bounded attribution: 54 of 63 sources were examined at abstract/status depth. Five linked errata remain flagged with unexamined correction details, and three linked notices carry no supplied PMID, so those relationships cannot be checked further from the record. No literature search was re-run, so completeness at the 2026-10-08 cutoff is not certified.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Ling JP, Pletnikova O, Troncoso JC et al. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science (New York, N.Y.). 2015. PMID 26250685. DOI: 10.1126/science.aab0983. Access: full_text_partial. Study: PMID26250685.

2. Brown AL, Wilkins OG, Keuss MJ et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022. PMID 35197628. DOI: 10.1038/s41586-022-04436-3. Access: abstract_metadata. Study: PMID35197628.

3. Seddighi S, Qi YA, Brown AL et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. Science translational medicine. 2024. PMID 38277467. DOI: 10.1126/scitranslmed.adg7162. Access: abstract_metadata. Study: PMID38277467.

4. Baughn MW, Melamed Z, López-Erauskin J et al. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. Science (New York, N.Y.). 2023. PMID 36927019. DOI: 10.1126/science.abq5622. Access: full_text_partial. Study: PMID36927019.

5. Irwin KE, Jasin P, Braunstein KE et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. Nature medicine. 2024. PMID 38278991. DOI: 10.1038/s41591-023-02788-5. Access: abstract_metadata. Study: PMID38278991.

6. Prudencio M, Humphrey J, Pickles S et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. The Journal of clinical investigation. 2020. PMID 32790644. DOI: 10.1172/JCI139741. Access: abstract_metadata. Study: PMID32790644.

7. Ma XR, Prudencio M, Koike Y et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022. PMID 35197626. DOI: 10.1038/s41586-022-04424-7. Access: full_text_partial. Study: PMID35197626.

8. Klim JR, Williams LA, Limone F et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nature neuroscience. 2019. PMID 30643292. DOI: 10.1038/s41593-018-0300-4. Access: abstract_metadata. Study: PMID30643292.

9. Melamed Z, López-Erauskin J, Baughn MW et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nature neuroscience. 2019. PMID 30643298. DOI: 10.1038/s41593-018-0293-z. Access: abstract_metadata. Study: PMID30643298.

10. Spence H, Waldron FM, Saleeb RS et al. RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta neuropathologica. 2024. PMID 38443601. DOI: 10.1007/s00401-024-02705-1. Access: abstract_metadata. Study: PMID38443601.

11. Huang WP, Ellis BCS, Hodgson RE et al. Stress-induced TDP-43 nuclear condensation causes splicing loss of function and STMN2 depletion. Cell reports. 2024. PMID 38941189. DOI: 10.1016/j.celrep.2024.114421. Access: abstract_metadata. Study: PMID38941189.

12. Krus KL, Strickland A, Yamada Y et al. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell reports. 2022. PMID 35767949. DOI: 10.1016/j.celrep.2022.111001. Access: abstract_metadata. Study: PMID35767949.

13. Wang W, Wang L, Lu J et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nature medicine. 2016. PMID 27348499. DOI: 10.1038/nm.4130. Access: abstract_metadata. Study: PMID27348499.

14. Mann JR, Gleixner AM, Mauna JC et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron. 2019. PMID 30826182. DOI: 10.1016/j.neuron.2019.01.048. Access: abstract_metadata. Study: PMID30826182.

15. Walker AK, Spiller KJ, Ge G et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta neuropathologica. 2015. PMID 26197969. DOI: 10.1007/s00401-015-1460-x. Access: abstract_metadata. Study: PMID26197969.

16. Becker LA, Huang B, Bieri G et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017. PMID 28405022. DOI: 10.1038/nature22038. Access: abstract_metadata. Study: PMID28405022.

17. Joseph BJ, Marshall KA, Harley P et al. TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD. Nature neuroscience. 2025. PMID 41174170. DOI: 10.1038/s41593-025-02096-w. Access: abstract_metadata. Study: PMID41174170.

18. Bryce-Smith S, Brown AL, Chien MZYJ et al. TDP-43 loss induces cryptic polyadenylation in ALS/FTD. Nature neuroscience. 2025. PMID 41120751. DOI: 10.1038/s41593-025-02050-w. Access: abstract_metadata. Study: PMID41120751.

19. Coyne AN, Baskerville V, Zaepfel BL et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Science translational medicine. 2021. PMID 34321318. DOI: 10.1126/scitranslmed.abe1923. Access: abstract_metadata. Study: PMID34321318.

20. Guo L, Kim HJ, Wang H et al. Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains. Cell. 2018. PMID 29677512. DOI: 10.1016/j.cell.2018.03.002. Access: abstract_metadata. Study: PMID29677512.

21. Hofweber M, Hutten S, Bourgeois B et al. Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation. Cell. 2018. PMID 29677514. DOI: 10.1016/j.cell.2018.03.004. Access: abstract_metadata. Study: PMID29677514.

22. Mackenzie IR, Nicholson AM, Sarkar M et al. TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron. 2017. PMID 28817800. DOI: 10.1016/j.neuron.2017.07.025. Access: abstract_metadata. Study: PMID28817800.

23. Fang MY, Markmiller S, Vu AQ et al. Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD. Neuron. 2019. PMID 31272829. DOI: 10.1016/j.neuron.2019.05.048. Access: abstract_metadata. Study: PMID31272829.

24. Korben VA, Lyashchenko AK, Blanco-Redondo B et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nature medicine. 2022. PMID 35075293. DOI: 10.1038/s41591-021-01615-z. Access: full_text_partial. Study: PMID35075293. Author-name discrepancy: this reference is printed as PubMed renders the record ("Korben VA"), while the prose above refers to the same first author as "Korobeynikov". Reference 49 (PMID 40414239) lists "Korobeynikov VA" with the same initials and the same senior author and centre, so the two forms very probably denote one person, but which form is correct cannot be settled from the accessible record, so neither has been altered.

25. Arseni D, Hasegawa M, Murzin AG et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022. PMID 34880495. DOI: 10.1038/s41586-021-04199-3. Access: abstract_metadata. Study: PMID34880495.

26. Conicella AE, Dignon GL, Zerze GH et al. TDP-43 α-helical structure tunes liquid-liquid phase separation and function. Proceedings of the National Academy of Sciences of the United States of America. 2020. PMID 32132204. DOI: 10.1073/pnas.1912055117. Access: abstract_metadata. Study: PMID32132204.

27. Arai T, Hasegawa M, Akiyama H et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and biophysical research communications. 2006. PMID 17084815. DOI: 10.1016/j.bbrc.2006.10.093. Access: abstract_metadata. Study: PMID17084815.

28. Belchikov N, Hu W, Fan L et al. A single-cell, long-read, isoform-resolved case-control study of FTD reveals cell-type-specific and broad splicing dysregulation in human brain. Cell reports. 2025. PMID 40913764. DOI: 10.1016/j.celrep.2025.116198. Access: abstract_metadata. Study: PMID40913764.

29. Mackenzie IR, Munoz DG, Kusaka H et al. Distinct pathological subtypes of FTLD-FUS. Acta neuropathologica. 2011. PMID 21052700. DOI: 10.1007/s00401-010-0764-0. Access: abstract_metadata. Study: PMID21052700.

30. López-Erauskin J, Bravo-Hernandez M, Presa M et al. Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation. Nature neuroscience. 2024. PMID 37996528. DOI: 10.1038/s41593-023-01496-0. Access: abstract_metadata. Study: PMID37996528.

31. Guo C, Chen K, Vatsavayai S et al. Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction. Science translational medicine. 2026. PMID 42234776. DOI: 10.1126/scitranslmed.aeb8517. Access: abstract_metadata. Study: PMID42234776.

32. Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (New York, N.Y.). 2006. PMID 17023659. DOI: 10.1126/science.1134108. Access: abstract_metadata. Study: PMID17023659.

33. Sreedharan J, Blair IP, Tripathi VB et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (New York, N.Y.). 2008. PMID 18309045. DOI: 10.1126/science.1154584. Access: abstract_metadata. Study: PMID18309045.

34. Vance C, Rogelj B, Hortobágyi T et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (New York, N.Y.). 2009. PMID 19251628. DOI: 10.1126/science.1165942. Access: abstract_metadata. Study: PMID19251628.

35. Kwiatkowski TJ, Bosco DA, Leclerc AL et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (New York, N.Y.). 2009. PMID 19251627. DOI: 10.1126/science.1166066. Access: abstract_metadata. Study: PMID19251627.

36. Picchiarelli G, Demestre M, Zuko A et al. FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nature neuroscience. 2019. PMID 31591561. DOI: 10.1038/s41593-019-0498-9. Access: abstract_metadata. Study: PMID31591561.

37. Sleigh JN, Tosolini AP, Gordon D et al. Mice Carrying ALS Mutant TDP-43, but Not Mutant FUS, Display In Vivo Defects in Axonal Transport of Signaling Endosomes. Cell reports. 2020. PMID 32187538. DOI: 10.1016/j.celrep.2020.02.078. Access: abstract_metadata. Study: PMID32187538.

38. Scekic-Zahirovic J, Sendscheid O, El Oussini H et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. The EMBO journal. 2016. PMID 26951610. DOI: 10.15252/embj.201592559. Access: full_text_partial. Study: PMID26951610.

39. Sharma A, Lyashchenko AK, Lu L et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nature communications. 2016. PMID 26842965. DOI: 10.1038/ncomms10465. Access: abstract_metadata. Study: PMID26842965.

40. Devoy A, Kalmar B, Stewart M et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in 'FUSDelta14' knockin mice. Brain : a journal of neurology. 2017. PMID 29053787. DOI: 10.1093/brain/awx248. Access: full_text_partial. Study: PMID29053787.

41. Humphrey J, Birsa N, Milioto C et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic acids research. 2020. PMID 32479602. DOI: 10.1093/nar/gkaa410. Access: abstract_metadata. Study: PMID32479602.

42. Scekic-Zahirovic J, Oussini HE, Mersmann S et al. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta neuropathologica. 2017. PMID 28243725. DOI: 10.1007/s00401-017-1687-9. Access: abstract_metadata. Study: PMID28243725.

43. Arnold ES, Ling SC, Huelga SC et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences of the United States of America. 2013. PMID 23382207. DOI: 10.1073/pnas.1222809110. Access: abstract_metadata. Study: PMID23382207.

44. Ditsworth D, Maldonado M, McAlonis-Downes M et al. Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta neuropathologica. 2017. PMID 28357566. DOI: 10.1007/s00401-017-1698-6. Access: abstract_metadata. Study: PMID28357566.

45. White MA, Kim E, Duffy A et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nature neuroscience. 2018. PMID 29556029. DOI: 10.1038/s41593-018-0113-5. Access: abstract_metadata. Study: PMID29556029.

46. Igaz LM, Kwong LK, Lee EB et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. The Journal of clinical investigation. 2011. PMID 21206091. DOI: 10.1172/JCI44867. Access: abstract_metadata. Study: PMID21206091.

47. Maharana S, Wang J, Papadopoulos DK et al. RNA buffers the phase separation behavior of prion-like RNA binding proteins. Science (New York, N.Y.). 2018. PMID 29650702. DOI: 10.1126/science.aar7366. Access: abstract_metadata. Study: PMID29650702.

48. Gruijs da Silva LA, Simonetti F, Hutten S et al. Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation. The EMBO journal. 2022. PMID 35112738. DOI: 10.15252/embj.2021108443. Access: abstract_metadata. Study: PMID35112738.

49. Shneider NA, Harms MB, Korobeynikov VA et al. Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. Lancet (London, England). 2025. PMID 40414239. DOI: 10.1016/S0140-6736(25)00513-6. Access: full_text_partial. Study: PMID40414239.

50. Lu S, Hu J, Arogundade OA et al. Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. Nature cell biology. 2022. PMID 36075972. DOI: 10.1038/s41556-022-00988-8. Access: abstract_metadata. Study: PMID36075972.

51. Pérez-Berlanga M, Wiersma VI, Zbinden A et al. Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns. The EMBO journal. 2023. PMID 37431963. DOI: 10.15252/embj.2022111719. Access: abstract_metadata. Study: PMID37431963.

52. Yu H, Lu S, Gasior K et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science (New York, N.Y.). 2021. PMID 33335017. DOI: 10.1126/science.abb4309. Access: abstract_metadata. Study: PMID33335017.

53. Armakola M, Higgins MJ, Figley MD et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nature genetics. 2012. PMID 23104007. DOI: 10.1038/ng.2434. Access: abstract_metadata. Study: PMID23104007.

54. Barmada SJ, Skibinski G, Korb E et al. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2010. PMID 20071528. DOI: 10.1523/JNEUROSCI.4988-09.2010. Access: abstract_metadata. Study: PMID20071528.

55. Ervilha Pereira P, Schuermans N, Meylemans A et al. C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD. Acta neuropathologica. 2023. PMID 37000196. DOI: 10.1007/s00401-023-02565-1. Access: abstract_metadata. Study: PMID37000196.

56. Wu LS, Cheng WC, Shen CK et al. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. The Journal of biological chemistry. 2012. PMID 22718760. DOI: 10.1074/jbc.M112.359000. Access: abstract_metadata. Study: PMID22718760.

57. Yang M, Wang Q, Yan R et al. A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of PKN1. Nature communications. 2026. PMID 41720774. DOI: 10.1038/s41467-026-68916-0. Access: abstract_metadata. Study: PMID41720774.

58. Necarsulmer JC, Simon JM, Evangelista BA et al. RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy. eLife. 2023. PMID 37819053. DOI: 10.7554/eLife.85921. Access: abstract_metadata. Study: PMID37819053.

59. Chou CC, Zhang Y, Umoh ME et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nature neuroscience. 2018. PMID 29311743. DOI: 10.1038/s41593-017-0047-3. Access: abstract_metadata. Study: PMID29311743.

60. Rothstein JD, Keeley O, Warlick C et al. Sporadic ALS induced pluripotent stem cell derived neurons reveal hallmarks of TDP-43 loss of function. Nature communications. 2025. PMID 40753166. DOI: 10.1038/s41467-025-62482-7. Access: abstract_metadata. Study: PMID40753166.

61. Bolognesi B, Faure AJ, Seuma M et al. The mutational landscape of a prion-like domain. Nature communications. 2019. PMID 31519910. DOI: 10.1038/s41467-019-12101-z. Access: full_text_partial. Study: PMID31519910.

62. Cragnaz L, Klima R, Skoko N et al. Aggregate formation prevents dTDP-43 neurotoxicity in the Drosophila melanogaster eye. Neurobiology of disease. 2014. PMID 25088712. DOI: 10.1016/j.nbd.2014.07.009. Access: abstract_metadata. Study: PMID25088712.

63. Donde A, Sun M, Ling JP et al. Splicing repression is a major function of TDP-43 in motor neurons. Acta neuropathologica. 2019. PMID 31332509. DOI: 10.1007/s00401-019-02042-8. Access: full_text_partial. Study: PMID31332509.

Source-specific evidence cards

[1] TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.

Shows: UG-dependent cryptic splicing and chimeric repressor cell-survival rescue.

Does not show: Whole-body disease not tested; human mouse target sequences differ.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Main text:paragraph4, 1:Main text:paragraph5, 1:Main text:paragraph6, 1:Main text:paragraph7, 1:Main text:paragraph8, 1:Main text:paragraph9, 1:Main text:paragraph10, 1:Main text:paragraph11, 1:Main text:paragraph12, 1:Main text. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[2] TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A.

Shows: UNC13A risk variants potentiate TDP-dependent cryptic splicing and protein loss.

Does not show: Natural risk is conditional; erratum38890465 details unaudited.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Erratum in: PMID 38890465. Subclaims: SC2.

[3] Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD.

Shows: Cryptic transcripts yield detectable novel peptides including CSF signals.

Does not show: Peptide presence does not prove toxicity or initiating causality.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Update of: PMID 36747793. Subclaims: SC2, SC5.

[4] Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.

Shows: Endogenous splice-site edits and ASOs restore STMN2 and human axon regeneration.

Does not show: Mouse target engagement is not disease-course rescue; regenerated injury axons are restricted endpoints.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 0:A GU-motif confers TDP-43 binding-dependent maturation of stathmin-2 pre-mRNA, 1:TDP-43 binding sterically blocks cryptic splicing and polyadenylation of STMN2, 2:Genomic disruption of exon 2a cryptic splice site protects against misprocessing, 6:rASOs restore axonal regeneration capacity in TDP-43 deficient motor neurons, 7:rASO-mediated restoration of Stmn2 pre-mRNA processing in the mammalian CNS. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[5] A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.

Shows: Cryptic HDGFL2 biomarker can precede neurofilament rise.

Does not show: Temporal biomarker not causal intervention; erratum38580817 details unaudited.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Update of: PMID 36789434; Erratum in: PMID 38580817. Subclaims: SC1, SC2.

[6] Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.

Shows: Truncated STMN2 tracks FTLD-TDP rather than FTLD-tau.

Does not show: Postmortem association and variant-specific nuclear dysfunction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[7] TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.

Shows: TDP depletion reduces UNC13A; risk haplotypes amplify cryptic exon use and RNA-binding competent rescue.

Does not show: Human survival association not randomized rescue; binding assay differs from companion Brown paper.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Main:paragraph2, 0:Main:paragraph5, 0:Main:paragraph6, 0:Main:paragraph18, 0:Main:paragraph19, 0:Main:paragraph20, 0:Main:paragraph21. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[8] ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair.

Shows: STMN2 loss follows TDP depletion; stabilization restores axonal regeneration.

Does not show: Injury regeneration in culture is not ALS survival.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[9] Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.

Shows: STMN2 correction restores axon regeneration after nuclear TDP dysfunction.

Does not show: Shared target and culture challenge; disease trajectory untested.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[10] RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS.

Shows: Nuclear TDP abnormalities and cryptic splicing map to earlier regional stages than cytoplasmic burden.

Does not show: Inferred timing from tissue is not longitudinal causal tracking; matched journal replaces preprint.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[11] Stress-induced TDP-43 nuclear condensation causes splicing loss of function and STMN2 depletion.

Shows: RNA-depleted nuclear condensates accompany persistent STMN2 splicing loss.

Does not show: Forced stress and coupled state-function changes do not identify sporadic initiation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[12] Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy.

Shows: STMN2 is needed for motor-unit maintenance; knockout denervates fast-fatigable NMJs.

Does not show: No motor-neuron or axon degeneration in this model; not full ALS phenocopy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[13] The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity.

Shows: Blocking mitochondrial TDP import rescues neuronal and behavioral phenotypes.

Does not show: Overexpression and broad mitochondrial intervention do not isolate macroscopic aggregates.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[14] RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.

Shows: Forced cytoplasmic assemblies are toxic and RNA antagonism reduces inclusion/toxicity.

Does not show: Optogenetic assembly and coupled effects cap endogenous necessity inference.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[15] Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.

Shows: Transgene suppression improves motor course and survival with restoration of nuclear TDP.

Does not show: Both arms and total protein change together; overexpression model.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[16] Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.

Shows: Ataxin2 deletion or ASO extends survival and lowers pathology.

Does not show: Pleiotropic change does not selectively identify aggregate toxicity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[17] TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS/FTD.

Shows: KCNQ2 cryptic exon produces ER-associated protein and hyperexcitability corrected by ASO.

Does not show: Cell-function rescue not organismal or clinical rescue.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[18] TDP-43 loss induces cryptic polyadenylation in ALS/FTD.

Shows: TDP loss alters cryptic polyadenylation with both stability-increasing and decreasing effects.

Does not show: Not all aberrant RNAs undergo NMD or cause neuronal death.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Update of: PMID 38313254. Subclaims: SC2.

[19] Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS.

Shows: CHMP7 lowering restores pore/Ran/RNA defects and protects against glutamate challenge.

Does not show: Upstream transport perturbation and challenge survival not spontaneous disease course.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

[20] Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains.

Shows: Nuclear import receptors counter phase transitions and rescue functional or degenerative outcomes.

Does not show: Import and chaperoning change together across forced models.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[21] Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation.

Shows: Transportin and arginine methylation regulate FUS condensation and localization.

Does not show: Material-state mechanism does not establish clinical primary cause.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[22] TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics.

Shows: TIA1 variants link altered granule dynamics to selected ALS/FTD families.

Does not show: Familial association and engineered stress cannot generalize across sporadic disease.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[23] Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD.

Shows: Small molecules modify stress-granule composition and TDP puncta.

Does not show: Puncta reduction lacks organismal trajectory endpoint.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[24] Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.

Shows: Dose and conditional FUS contrasts identify mutant toxicity; P1 ION363 prevents motor-neuron loss and denervation while active.

Does not show: No overt motor phenotype in initial heterozygotes; prophylactic lowering changes soluble and insoluble FUS; one patient cannot establish efficacy.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph3, 1:Results:paragraph36, 1:Results:paragraph49, 1:Results:paragraph52, 1:Results:paragraph53, 1:Results:paragraph59. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[25] Structure of pathological TDP-43 filaments from ALS with FTLD.

Shows: Disease filaments have structures distinct from reconstructed in vitro fibrils.

Does not show: Structural identity is not toxicity or necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[26] TDP-43 α-helical structure tunes liquid-liquid phase separation and function.

Shows: Helical changes can enhance phase separation and splicing function.

Does not show: Condensation is not intrinsically pathogenic; reporter endpoints.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[27] TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Shows: TDP protein identified in selected disease inclusions.

Does not show: Postmortem presence cannot assign cause.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[28] A single-cell, long-read, isoform-resolved case-control study of FTD reveals cell-type-specific and broad splicing dysregulation in human brain.

Shows: Cell-layer analysis exposes splicing defects masked by bulk RNA.

Does not show: Defined genetic FTD subset and observational tissue.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[29] Distinct pathological subtypes of FTLD-FUS.

Shows: Distinct FUS-positive TDP/tau-negative subtypes constrain a uniform protein account.

Does not show: Selected case series cannot estimate all-population prevalence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC5.

[30] Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation.

Shows: STMN2 loss alters axon caliber conduction denervation and motor behavior.

Does not show: Not selective rescue of endogenous sporadic TDP disease.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[31] Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction.

Shows: Combined correction of KALRN RAP1GAP SYT7 KCNQ2 nearly restores synaptic function after TDP loss.

Does not show: Multitarget culture rescue not systemic survival; journal report deduplicated from preprint.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Update of: PMID 40949955. Subclaims: SC2.

[32] Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Shows: Modified ubiquitinated TDP defines a shared pathology class.

Does not show: End-stage association does not resolve toxic species.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[33] TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.

Shows: Segregating variants support gene-level etiology; engineered developmental toxicity.

Does not show: Gene causality does not prove aggregates or all sporadic mechanism.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[34] Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.

Shows: FUS mutations segregate in defined ALS families with abnormal localization.

Does not show: Familial etiology is not universal sporadic mechanism.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[35] Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis.

Shows: Multiple familial mutations alter FUS localization.

Does not show: Localization and gene effects remain coupled; no aggregate-selective intervention.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[36] FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis.

Shows: Muscle-intrinsic postsynaptic defects precede motor-neuron loss.

Does not show: Same mutant lineage reused; erratum42463858 details unaudited.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Erratum in: PMID 42463858. Subclaims: SC3, SC5.

[37] Mice Carrying ALS Mutant TDP-43, but Not Mutant FUS, Display In Vivo Defects in Axonal Transport of Signaling Endosomes.

Shows: TDP transport defects are absent in FUSDelta14 despite neuron loss.

Does not show: Shared FUS line; separates one pathway rather than excluding all cytoplasmic toxicity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[38] Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss.

Shows: Mutant but not null causes neonatal motor loss; allele reversion rescues cell bodies.

Does not show: Perinatal homozygous model; death not rescued; WT restoration removes mutant and restores nuclear function together.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph18, 1:Results:paragraph73, 1:Results:paragraph78, 1:Results:paragraph79, 1:Results:paragraph83. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[39] ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function.

Shows: Mutant gain induces degeneration while postnatal FUS loss alone does not.

Does not show: Transgenic dose and developmental timing constrain generalization.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[40] Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in 'FUSDelta14' knockin mice.

Shows: Equivalent total FUS dosage yields progressive motor loss without insoluble FUS or histological inclusions.

Does not show: Specific mutation and mouse lifespan; absence at tested stages does not exclude small assemblies.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Results:paragraph0, 2:Results:paragraph3, 2:Results:paragraph6, 2:Results:paragraph8, 2:Results:paragraph12, 2:Results:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[41] FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention.

Shows: FUS autoregulatory splicing and expression networks differ across mutant and loss states.

Does not show: Same knock-in family; transcriptome perturbation not sufficient causal course proof.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[42] Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis.

Shows: Motor-neuron WT allele reversion saves cell bodies but only delays symptoms.

Does not show: Residual axonal and neighboring-cell pathology limits whole-course rescue.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[43] ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43.

Shows: Adult motor disease and RNA gain/loss occur without insoluble aggregates or nuclear depletion.

Does not show: Transgene is not an endogenous knock-in; small assemblies not excluded.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[44] Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis.

Shows: Motor-neuron mutant excision prevents cell-body loss but not all axon/glial progression.

Does not show: Cell restriction and incomplete rescue argue against neuron-only single mechanism.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[45] TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD.

Shows: Autoregulation and RNA function are perturbed with cognitive/interneuron phenotypes.

Does not show: KI does not ensure unchanged total dose; erratum29872124 details unaudited.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Erratum in: PMID 29872124. Subclaims: SC2, SC4.

[46] Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.

Shows: Degeneration occurs with few inclusions and downregulation of endogenous TDP.

Does not show: Overexpression and autoregulation confound compartment-specific attribution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[47] RNA buffers the phase separation behavior of prion-like RNA binding proteins.

Shows: RNA concentration and binding tune RBP demixing and cell toxicity.

Does not show: RNA buffering is not proof of initiating disease failure in vivo.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[48] Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation.

Shows: Phosphomimetic changes suppress aggregation while retaining import and RNA function.

Does not show: Protective disease-course effects are proposed rather than established.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[49] Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.

Shows: Target engagement and neurofilament reductions coexist with one functional recovery and frequent continued decline.

Does not show: Open-label heterogeneous variants and dosing; prior single patient reused; erratum40849137 unaudited.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 2:Results:paragraph1, 2:Results:paragraph2, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph6, 2:Results:paragraph7, 2:Results:paragraph8. No complete-paper or supplement audit claimed. Erratum in: PMID 40849137. Subclaims: SC3, SC5.

[50] Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition.

Shows: HSPB1 restrains cytoplasmic gel/fibril states and is reduced in some affected neurons.

Does not show: Forced stress and postmortem chaperone loss cannot identify endogenous necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[51] Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns.

Shows: Structured oligomer and RNA-binding changes alter stability splicing and aggregation.

Does not show: Properties change together; journal 2023 replaces the repository/preprint date.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[52] HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells.

Shows: HSP70/ATP regulate liquid shells and solidification of TDP assemblies.

Does not show: Proteasome challenge and nuclear material state are not sporadic ALS initiation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[53] Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.

Shows: DBR1-dependent RNA lariats buffer TDP toxicity.

Does not show: Forced expression and RNA pleiotropy; no disease survival.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[54] Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis.

Shows: Diffuse cytoplasmic TDP predicts death; inclusion presence does not increase measured death risk.

Does not show: Tagged overexpression; lack of risk association does not prove inclusions protective.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[55] C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD.

Shows: Aggregation-prone frameshift is less neuron-toxic with partial functional loss.

Does not show: Myopathy is a different phenotype; not broad protective aggregate evidence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[56] Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice.

Shows: Conditional loss yields progressive motor-neuron loss and glial activation.

Does not show: Loss of essential protein is not selective cryptic-splicing disruption alone.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[57] A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of PKN1.

Shows: A cryptic PKN peptide escaping NMD can impair cognition in an expression model.

Does not show: Ectopic peptide toxicity is not endogenous ALS necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[58] RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy.

Shows: RNA-binding impairment precedes cognitive and pathological progression.

Does not show: Acetyl-mimic mutation is not identical to a natural acetylation state.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Update of: PMID not supplied; Update of: PMID not supplied; Update of: PMID not supplied. Subclaims: SC2, SC4.

[59] TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD.

Shows: TDP pathological assemblies associate with nuclear-pore disruption.

Does not show: Cell assays and tissue association lack organismal trajectory rescue; journal 2018 replaces conference 2017.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC5.

[60] Sporadic ALS induced pluripotent stem cell derived neurons reveal hallmarks of TDP-43 loss of function.

Shows: Variable TDP loss signatures track nuclear pores; POM121 repair restores RNA function.

Does not show: Cellular repair and donor association not clinical course rescue.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

[61] The mutational landscape of a prion-like domain.

Shows: Hydrophobic solid-like aggregates correlate with less toxicity than dynamic peripheral foci.

Does not show: Yeast forced expression and multifactorial sequence changes; not proof all human aggregates protect.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph9, 1:Results:paragraph10. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[62] Aggregate formation prevents dTDP-43 neurotoxicity in the Drosophila melanogaster eye.

Shows: Artificial aggregates sequester TBPH and protect the eye from overexpression toxicity.

Does not show: Developmental eye context and TDP dispensability limit disease relevance.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[63] Splicing repression is a major function of TDP-43 in motor neurons.

Shows: A chimeric splicing repressor rescues motor function and extends mouse median survival by 29 weeks in two cohorts.

Does not show: Neonatal AAV and knockout not sporadic initiation; litter-level randomization and delivery attrition; same Ling programme.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Materials and Methods:paragraph9, 1:Materials and Methods:paragraph10, 1:Materials and Methods:paragraph11, 1:Materials and Methods:paragraph12, 1:Materials and Methods:paragraph13, 2:Results:paragraph0, 2:Results:paragraph2, 2:Results:paragraph3, 2:Results:paragraph4, 2:Results:paragraph5, 2:Results:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• rbp-aggregation-als-ftd.review.md
• rbp-aggregation-als-ftd.scorecard.json
• reader-summary.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 63 · load-bearing claims: 69 · verified: 69 · unverified: 0 · contradicted: 0 · schema 5.3